Experimental virus vaccine takes on multiple cancers in early trial

NCT ID NCT05492682

Recruiting now Disease control Sponsor: Valo Therapeutics Oy Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial is testing a new virus-based cancer vaccine (PeptiCRAd-1) combined with the immunotherapy drug pembrolizumab in 15 people with various solid tumors like melanoma, triple-negative breast cancer, and lung cancer. The main goal is to see if the combination is safe and whether it sparks an immune response against cancer. All participants receive the vaccine, a single dose of cyclophosphamide, and six doses of pembrolizumab.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: PeptiCRAd-1 (a virus-based cancer vaccine) combined with pembrolizumab (an immunotherapy drug)
What this could lead to: If this early trial shows the combination is safe and boosts the immune system against tumors, it could point toward a new treatment option for several hard-to-treat cancers.
What could go wrong: This is a very small, early-phase (Phase 1) study with only 15 people. The main goal is safety, not effectiveness. The treatment may not shrink tumors or could cause serious side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm cutaneous melanoma melanoma myxoid liposarcoma myxoid/round cell liposarcoma non-small cell lung carcinoma osteosarcoma sarcoma synovial sarcoma triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLORECTAL CANCER MELANOMA (SKIN) MYXOID LIPOSARCOMA NON-SMALL CELL LUNG CANCER OSTEOSARCOMA SARCOMA SYNOVIAL SARCOMA TRIPLE NEGATIVE BREAST CANCER

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

IRCCS Istituto Clinico Humanitas
NOT_YET_RECRUITING

Milan, Italy
IRCCS Ospedale San Raffaele
NOT_YET_RECRUITING

Milan, Italy
Istituto di Candiolo Fondazione del Piemonte per l'oncologia IRCCS
RECRUITING

Candiolo, Italy
Krankenhaus Nordwest
ACTIVE_NOT_RECRUITING

Frankfurt, Germany
National Center for Tumor Diseases
COMPLETED

Heidelberg, Germany
Università di Napoli Federico II
NOT_YET_RECRUITING

Naples, Italy
Universitätsklinikum Tübingen
COMPLETED

Tübingen, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.